SLS vs SNDX: fair value comparison
SELLAS Life Sciences Group, Inc. and Syndax Pharmaceuticals, Inc. · Updated 2026-10-19
SLS has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. SNDX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, SLS currently ranks higher by quality score.
| SLS | SNDX | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $9.98 | $12.90 |
| 12-month range | $1.39–$15.46 | $12.90–$25.15 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #267 of 301 Healthcare | #269 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | High |
| Margin trend | Expanding | Stable |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Mixed | Downtrend |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: SLS fair value analysis · SNDX fair value analysis